Molecular Docking and Drug Kinetics Assessment for Structure-Based Drug Design of New Piperazine-Containing Hydrazone Derivatives as Effective Alzheimer Inhibitors
DOI:
https://doi.org/10.54987/jobimb.v12i2.1016Keywords:
Alzheimer's Disease, Computer-aided drug design, Complex mechanism, Binding energy, PharmacokineticsAbstract
The neurodegenerative condition known as Alzheimer's disease (AD) impairs cognitive function and produces dementia in older people. The disease's precise mechanism is still a mystery. Four drugs are available. However, they all have a long list of adverse effects and only help people with their warning signs. Medicinal chemists are searching for ways to treat this disease. There is discussion about creating and using a new class of multifunctional small molecule inhibitors. The hydrazone scaffold was used to create a wide range of chemicals. This is because hydrazone derivatives may disrupt the self-assembly of amyloid beta (A), one of the factors that cause fibrils and oligomers. They may also reverse the effects of harmful compounds like free radicals on effective therapeutic agents like medications that penetrate the central nervous system. Structure-based drug design methods were used in this investigation. A protein target (code ID 4EY7) was selected based on published literature research and factors like a lower resolution value (2.35), no mutation, Homo sapiens, and the X-ray diffraction technique. Fifteen Hydrazone derivatives with increased interactions, higher binding scores, and improved drug-like properties and drug kinetic parameters were designed using the protein target, engineered to interact with compounds of interest (a lead compound with a higher binding energy). Promising pharmacotherapeutic drugs for AD treatment may be developed using the results of these investigations.
References
Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M. Multidomain interventions to prevent cognitive impairment, Alzheimer's disease, and dementia: From FINGER to World-Wide FINGERS. J Prev Alzheimers Dis. 2020;7(1):29-36.
Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease. Clin Biochem. 2019;72:87-9.
Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, Medeiros R. Inflammation: the link between comorbidities, genetics, and Alzheimer's disease. J Neuroinflammation. 2018;15(1):1-26.
Ramos-Inza S, Aydillo C, Sanmartín C, Plano D. Thiazole moiety: an interesting scaffold for developing new antitumoral compounds. In: Heterocycles-synthesis and biological activities. IntechOpen; 2019.
AlFadly ED, Elzahhar PA, Tramarin A, Elkazaz S, Shaltout H, Abu-Serie MM, et al. Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase. Eur J Med Chem. 2019;167:161-86.
Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer's disease: current and future pharmacotherapy options. J Alzheimers Dis. 2019;67(3):779-94.
Zerroug E, Belaidi S, Chtita S. Artificial neural network-based quantitative structure-activity relationships model and molecular docking for virtual screening of novel potent acetylcholinesterase inhibitors. J Chin Chem Soc. 2021;68(8):1379-99.
Pascoini AL, Federico LB, Arêas ALF, Verde BA, Freitas PG, Camps I. In silico development of new acetylcholinesterase inhibitors. J Biomol Struct Dyn. 2019;37(4):1007-21.
Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem. 2012;55(22):10282-6.
Kaya B, Özkay Y, Temel HE, Kaplanc?kl? ZA. Synthesis and biological evaluation of novel piperazine containing hydrazone derivatives. J Chem. 2016;2016:1-8.
Mohdee V, Parasuk V, Pancharoen U. Synergistic effect of thiourea and HCl on palladium(II) recovery: An investigation on chemical structures and thermodynamic stability via DFT. Arab J Chem. 2021;14(7):103196.
Bhowmick S, Saha A, AlFaris NA, ALTamimi JZ, ALOthman ZA, Aldayel TS, et al. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches. J Mol Graph Model. 2022;111:108113.
Arthur DE, Uzairu A. Molecular docking studies on the interaction of NCI anticancer analogues with human phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit. J King Saud Univ Sci. 2019;31(4):1151-66.
Azimi F, Ghasemi JB, Azizian H, Najafi M, Faramarzi MA, Saghaei L, et al. Design and synthesis of novel pyrazole-phenyl semicarbazone derivatives as potential ?-glucosidase inhibitor: kinetics and molecular dynamics simulation study. Int J Biol Macromol. 2021;166:1082-95.
Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5-W14.
Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. J Med Chem. 2001;44(12):1841-6.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-23.
Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000;43(21):3867-77.
Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem. 1999;1(1):55-68.
Teague SJ, Davis AM, Leeson PD, Oprea T. The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl. 1999;38(24):3743-8.
Volpe DA. Advances in cell-based permeability assays to screen drugs for intestinal absorption. Expert Opin Drug Discov. 2020;15(5):539-49.
Aswathy L, Jisha RS, Masand VH, Gajbhiye JM, Shibi IG. Design of novel amyloid ? aggregation inhibitors using QSAR, pharmacophore modeling, molecular docking and ADME prediction. In Silico Pharmacol. 2018;6(1):1-19.
Halim SA, Sikandari AG, Khan A, Wadood A, Fatmi MQ, Csuk R, et al. Structure-based virtual screening of tumor necrosis factor-? inhibitors by cheminformatics approaches and bio-molecular simulation. Biomolecules. 2021;11(2):329.
Abd Shukor MS, Abd Shukor MY. Molecular docking and dynamics studies show: Phytochemicals from Papaya leaves extracts as potential inhibitors of SARS-CoV-2 proteins targets and TNF-alpha and alpha thrombin human targets for combating COVID-19. AIMS Mol Sci. 2023;10(3):213-62.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ibrahim Abdulganiyyu Akinbo, Maimuna Shehu Rufa'i , Abduljelil Ajala, Abass Sambo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
